The June issue of ONCOLOGY is available on our website! View updates in NSCLC, spiradenocarcinoma, and multiple myeloma. https://lnkd.in/eEHq4AZ6
About us
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers. Contact us at: cancernetwork@mjhlifesciences.com Like us on Facebook: Cancer Network Follow us on Twitter: @CancerNetwrk
- Website
-
http://www.cancernetwork.com
External link for Cancer Network
- Industry
- Book and Periodical Publishing
- Company size
- 201-500 employees
- Headquarters
- Cranbury, New Jersey
- Type
- Privately Held
Locations
-
Primary
Get directions
Cranbury, New Jersey 08512, US
Employees at Cancer Network
Updates
-
Of 15 patients included in cohort A, 4 had a complete radiographic response, 6 had partial responses, and 1 had stable disease. https://lnkd.in/eehyrjKg #melsm #cancer #oncology
-
🚨 NEW ONCOLOGY on the Go podcast featuring Julie M. Vose, MD, MBA, and Avyakta Kallam, MD, discussing their careers in lymphoma. Listen to the full discussion on our website: https://lnkd.in/eDpzZ4GB #lymsm #cancer #oncology
-
-
Eftilagimod alfa, plus pembrolizumab, achieved high efficacy and a favorable safety profile for patients with recurrent or metastatic HNSCC with negative PD-L1 expression. https://lnkd.in/e5DZHhmT #hncsm #cancer #oncology
Eftilagimod Alfa Combo Appears Efficacious in Head and Neck Cancer
cancernetwork.com
-
In May 2024, liso-cel was approved by the FDA for patients with relapsed/refractory MCL who have received 2 prior lines of systemic therapy including a BTKi. https://lnkd.in/e3JexBsR #lymsm #cancer #oncology
FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma
cancernetwork.com
-
Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space. https://lnkd.in/eb9i2r-v #gicsm #cancer #oncology
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC
cancernetwork.com
-
View our top 5 articles of the week: 1. https://lnkd.in/ePN-xv5v 2. https://lnkd.in/e-Z7NPfm 3. https://lnkd.in/eSbnXewY 4. https://lnkd.in/e3Uax8fM 5. https://lnkd.in/e3Uax8fM
-
-
A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma. https://lnkd.in/eCUjNNhi #mmsm #cancer #oncology
Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study
cancernetwork.com
-
The panel concludes by offering key takeaways on the treatment of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy. https://lnkd.in/e6VGWMSd #mmsm #cancer #oncology
Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
cancernetwork.com
-
We observed clinical benefit in [patients with] CRC in a molecularly selected population and responses in [patients with] cancer that has not historically been responsive to FOLFIRI,” said Elisa Fontana, MD, PhD. https://lnkd.in/ekyny9Rj #gicsm #cancer #oncology
Lunresertib Combo Shows Responses in Advanced Pretreated GI Cancer Subtypes
cancernetwork.com